Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07141732 | Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy | recruiting | Phase 1 | 15 | Joint Stock Company European Medical CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07158710 | Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 159 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 |
| clinicaltrials |
| NCT06102525 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | recruiting | Phase 1 / Phase 2 | 43 | Rznomics, Inc.OTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05190315 | Chlorpromazine and Standard of Care in Glioblastoma | completed | Phase 1 | 10 | Mohammed MilhemOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT01478178 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 55 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03679754 | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | completed | Phase 1 | 36 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05390814 | [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma(FLUDALOC) | completed | Phase 1 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | active not recruiting | Phase 1 | 52 | Katmai Pharmaceuticals Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT07120620 | PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma(PriCoTTF) | completed | Phase 1 / Phase 2 | 33 | Sied KebirOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03636477 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | completed | Phase 1 | 21 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04963413 | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | terminated | Phase 1 | 6 | University of FloridaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05169944 | Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors(PNOC025) | completed | Phase 1 | 13 | University of California, San FranciscoOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773481 | BC008-1A Injection for Recurrent CNS WHO G4 Glioma | recruiting | Phase 1 | 40 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT04047706 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | enrolling by invitation | Phase 1 | 34 | Andrew P. GrovesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04121455 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients(GLORIA) | active not recruiting | Phase 1 / Phase 2 | 117 | TME Pharma AGINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | recruiting | Phase 1 | 66 | Orbus Therapeutics, Inc.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04019262 | Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 2 | John FlickingerOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02655601 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001(BMX-HGG) | completed | Phase 1 / Phase 2 | 177 | BioMimetix JV, LLCINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04749641 | Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma(ENACTING) | completed | Phase 1 | 16 | Yang ZhangOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT03452930 | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | completed | Phase 1 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02766699 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM(CerebralEDV) | completed | Phase 1 | 9 | Engeneic Pty LimitedINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06541665 | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | active not recruiting | Phase 1 | 20 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis(LMD) | terminated | Phase 1 | 9 | BiogenINDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT02311582 | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 55 | Washington University School of MedicineOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05187624 | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma | completed | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | May 22, 2025 | clinicaltrials |
| NCT03782415 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 64 | MediciNovaINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04342572 | Intra-arterial Chemotherapy for Retinoblastoma(IAC) | completed | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02507583 | Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | completed | Phase 1 | 33 | david andrewsOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT00329589 | A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients | completed | Phase 1 | 54 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 4 | In8bio Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2025source: clinicaltrials